Authors: Zakeri-Milani, Parvin
Mussa Farkhani, Samad
Shirani, Ali
Mohammadi, Samaneh
Shahbazi Mojarrad, Javid
Akbari, Jafar
Valizadeh, Hadi
Title: Cellular uptake and anti-tumor activity of gemcitabine conjugated with new amphiphilic cell penetrating peptides
Language (ISO): en
Abstract: Gemcitabine (Gem) is used as a single agent or in combination with other anticancer agents to treat many types of solid tumors. However, it has many limitations such as a short plasma half-life, dose-limiting toxicities and drug resistance. Cell-penetrating peptides (CPPs) are short peptides which may deliver a large variety of cargo mole- cules into the cancerous cells. The current study was designed to evaluate the antiproliferative activity of gemcita- bine chemically conjugated to CPPs. The peptides were synthesized using solid phase synthesis procedure. The uptake efficiency of CPPs into cells was examined by flow cytometry and fluorescent microscopy. The synthesized peptides were chemically conjugated to Gem and the in vitro cytotoxicity of conjugates was tested by MTT assay on A594 cell line. According to the obtained results, cellular uptake was increased with increasing the concentra- tion of CPPs. On the other hand the coupling of Gem with peptides containing block sequence of arginine (R5W3R4) and some alternating sequences (i.e. [RW]6 and [RW]3) exhibited improved antitumor activity of the drug. The findings in this study support the advantages of using cell-penetrating peptides for improving intracellular delivery of Gem into tumor as well as its activity.
Subject Headings: cell penetrating peptide
gemcitabine
toxicity
drug delivery
URI: http://hdl.handle.net/2003/36154
http://dx.doi.org/10.17877/DE290R-18170
Issue Date: 2017-05-09
Rights link: http://creativecommons.org/licenses/by/4.0/
Appears in Collections:Original Articles

Files in This Item:
File Description SizeFormat 
Valizadeh_09052017_proof.pdfDNB1.19 MBAdobe PDFView/Open


This item is protected by original copyright



This item is licensed under a Creative Commons License Creative Commons